On the one hand, PI3K inhibitors have been shown to slow gut motility via the loss of ICC [129], while on the other, gut motility would be expected to increase as a result of PI3K-mediated down regulation of neurotensin [130] and the associated loss of intestinal innervation [132]. Here, PIK3CD is linked to intrahepatic cholangiocarcinoma.